Results 271 to 280 of about 67,507 (290)
Some of the next articles are maybe not open access.
Resistance to Castration – Resistance to Drugs
2013Up to 70 % of newly diagnosed patients with advanced prostate cancer (PCa) will progress to castration-resistant prostate cancer (CRPC) and, in most cases (from 50 to 70 %), will develop hematogenous bone metastasis. Once PCa cells spread to the skeleton, cancer-related death becomes inevitable, with a death burden of more than 28,000 cases in 2012, in
openaire +2 more sources
Castration-Resistant Prostate Cancer
Drugs, 2010Until very recently, docetaxel was the only approved agent in castration-resistant prostate cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, several new agents with promising activity and a favourable toxicity profile have been developed and clinically investigated in the fields of hormonal, cytotoxic ...
Di Lorenzo G +4 more
openaire +4 more sources
[Metastatic castration-resistant prostate cancer].
Der Pathologe, 2021Metastatic castration-resistant prostate cancer (mCRPC) is considered as the final stage of the disease with limited therapeutic options to date. In this article, we review recent histopathologic and molecular pathologic findings that may expand our understanding of the disease and may lay, or have already laid the groundwork for the development of ...
Vanessa, Henriques +3 more
openaire +1 more source
[Castration-resistant prostate cancer (CRPC)].
Der Urologe. Ausg. A, 2014In merely a short period of time the comprehension of castration-resistant prostate cancer has evolved. It is now possible to clearly outline the exact definition and variance of the disease pattern. A wealth of new effective agents can be applied to extend the patient's life span and improve the quality of life.
W, Loidl, F, Luger, A, Roosen
openaire +1 more source
[Castration resistant prostate cancer 2015].
Aktuelle Urologie, 2016Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant
A S, Merseburger +3 more
openaire +1 more source
Metastatic castrate-resistant prostate cancer
Urologic Oncology: Seminars and Original Investigations, 2015openaire +2 more sources
Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine, 2020Bivas, Biswas +2 more
openaire +8 more sources